Why Sarepta Therapeutics (SRPT) Stock Continued to Climb Today

NEW YORK (TheStreet) -- Sarepta Therapeutics  (SRPT) continued to climb Tuesday after the company announced Monday it had received FDA guidance to apply for regulatory approval of its experimental Duchenne muscular dystrophy drug eteplirsen by the end of the year. The application would lead to a clinical study on a larger scale.

The stock surged 14.16% to $38.79, a $4.81 increase from its previous close of $33.98, at the close of trading on Tuesday. More than 4 million shares changed hands, nearly triple the average volume of 1,435,740. Sarepta had a range of $34.51 to $39.20 on Tuesday and holds a 52-week range of $12.12 to $55.61.

The company said in a statement it would bolster its FDA application with more safety and efficacy data from an earlier trial of the drug, along with a confirmatory study it plans to begin in the third quarter.

The FDA said in November that Sarepta's plan to file based on data at the time was premature, which caused a 64% drop in the  stock in just one day.
 
Robert W. Baird also increased its price target on Sarepta to $55 from $35 in the wake of Monday's news. The firm holds an "outperform" rating on the stock.
 

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

MoviePass Parent's Stock Plunges as AMC Announces Rival Program

MoviePass Parent's Stock Plunges as AMC Announces Rival Program

Dow Fluctuates, Nasdaq Strikes Record High

Dow Fluctuates, Nasdaq Strikes Record High

Square Jumps After Price Target Is Raised

Square Jumps After Price Target Is Raised

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low

Fed Chief Uncertain About Policy-Making as Unemployment Hits 18-Year Low

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up

Jim Cramer: Oil Needs to Go Down to See Worldwide Growth Pick Up